Amlodipine Global Regulatory Status: FDA Approval, Label Requirements, and Post-Market Safety

FDA Approval History and NDA Overview

Amlodipine received its original FDA approval on July 31, 1992, under New Drug Application (NDA) 019787, with Pfizer submitting the original sponsor data for the brand product Norvasc. The agency approved the drug across three indications simultaneously: essential hypertension, chronic stable angina, and vasospastic (Prinzmetal) angina. Few oral antihypertensives have held all three of these indications since their original approval date without a major label revision narrowing their scope.

The Original Approval Package

The 1992 approval was supported by a package of dose-ranging and efficacy studies conducted primarily in adults with mild-to-moderate hypertension. The FDA's pharmacology review noted that amlodipine's long plasma half-life of approximately 30 to 50 hours made once-daily dosing pharmacologically appropriate, a feature that distinguished it from earlier dihydropyridines such as nifedipine immediate-release. FDA Drugs@FDA, NDA 019787

Generic Entry and the Hatch-Waxman Timeline

Patent exclusivity for Norvasc expired in 2000. The first generic amlodipine besylate products entered the US market that same year. By 2005, more than a dozen abbreviated new drug applications (ANDAs) had been approved, driving the retail price down substantially. Today, amlodipine is one of the most widely dispensed drugs in the United States, with approximately 96 million prescriptions filled annually according to CDC prescribing data. CDC, National Ambulatory Medical Care Survey 2022

Pediatric Labeling Supplement

In 2008, the FDA accepted supplemental data supporting use in pediatric hypertension for patients aged 6 to 17 years. The approved pediatric dose is 2.5 mg to 5 mg once daily. This supplement was processed under the Pediatric Research Equity Act (PREA), which requires sponsors to conduct pediatric studies for drugs likely to be used in children. FDA Pediatric Labeling Information Database

What the Current FDA-Approved Label Says

The prescribing information for amlodipine (reference label, NDA 019787) defines the drug's approved uses, dosing instructions, contraindications, warnings, and monitoring requirements. Clinicians should always consult the current label rather than older references, because several sections were updated after post-market data accrued.

Approved Indications

The label lists three indications:

1. Hypertension, adults and pediatric patients aged 6 to 17 years. Amlodipine may be used as monotherapy or in combination with other antihypertensives.
2. Chronic stable angina, adults only. The drug reduces the frequency of anginal attacks and nitroglycerin consumption.
3. Vasospastic (Prinzmetal) angina, adults only. Controlled studies confirmed efficacy in coronary artery spasm.

The label does not carry an approved indication for heart failure with reduced ejection fraction, and it explicitly notes that amlodipine produced no benefit on mortality in the PRAISE-2 trial, a finding that shaped cautionary language about use in that population. PRAISE-2, JACC 2000

Dosing and Administration

Standard adult starting dose is 5 mg once daily, titrated to a maximum of 10 mg once daily based on response. Patients with hepatic impairment or who are elderly (typically aged 65 or older) should start at 2.5 mg once daily, because clearance is reduced. No renal dose adjustment is required for most patients, since amlodipine is metabolized primarily in the liver to inactive metabolites and only about 10% is excreted unchanged in the urine.

Contraindications and Warnings

The label lists known hypersensitivity to amlodipine as the sole contraindication. There is no black-box warning. The warnings and precautions section covers:

• Hypotension: Symptomatic hypotension is possible, especially in severely aortic-stenotic patients.
• Worsening angina and acute MI: Rarely, starting or increasing a dihydropyridine CCB dose has precipitated angina or MI, particularly in patients with obstructive coronary artery disease.
• Hepatic impairment: Because amlodipine is extensively hepatically metabolized, the label advises starting at the lower 2.5 mg dose in this population.

The label does not carry warnings for QT prolongation, drug-induced liver injury (DILI) as a class effect, or teratogenicity in pregnancy (though it is Pregnancy Category C under the old FDA system, meaning animal studies showed adverse effects but adequate human data are lacking). FDA Prescribing Information, Norvasc

EMA Authorization and European Regulatory Status

EMA Centralized and National Procedures

Amlodipine was not authorized through the EMA centralized procedure because it predates that system's broad scope (the centralized procedure became mandatory for certain drug classes in 1995 and was extended in later years). Instead, amlodipine received national marketing authorizations across EU member states. The EMA has, over time, published European Public Assessment Reports (EPARs) for several generic amlodipine products reviewed through the centralized procedure. These EPARs confirm bioequivalence to the reference product and list the same core indications approved in the United States. EMA Product Index

Core EU Label Differences

The EU Summary of Product Characteristics (SmPC) for amlodipine differs from the FDA label in several minor respects. The SmPC includes a specific caution for patients with hypertensive crisis, advising that intravenous antihypertensives be used instead of oral amlodipine in that acute setting, a point the FDA label addresses less explicitly. The EU label also provides more granular guidance on drug interactions with CYP3A4 inhibitors such as ketoconazole and ritonavir, flagging that plasma amlodipine concentrations may increase by up to 56% with strong inhibitors and recommending blood pressure monitoring in those combinations. EMA SmPC Guidance

Post-Market Referrals

No EU Article 31 or Article 107 referral has been completed specifically for amlodipine as a single-agent product, meaning the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has not issued a major class-wide signal action specific to this drug. The PRAC has reviewed CCB class signals as part of broader antihypertensive pharmacovigilance reviews, but no label-altering safety action has resulted for amlodipine specifically as of the last review date for this article.

Global Regulatory Approvals Beyond the US and EU

Amlodipine holds regulatory authorization in over 100 countries. The regulatory frameworks vary, but the core dossier submitted to most agencies traces back to the original Pfizer NDA and subsequent generic bioequivalence packages.

Health Canada

Health Canada authorized amlodipine under the brand name Norvasc and has since approved numerous generic versions. The Canadian Product Monograph (PM) aligns closely with the FDA label, including the same three indications and the recommendation to start at 2.5 mg in elderly or hepatically impaired patients. Health Canada's Drug Product Database lists amlodipine as a Schedule F drug, meaning it requires a prescription.

TGA (Australia)

The Therapeutic Goods Administration (TGA) in Australia authorized amlodipine and includes it on the Pharmaceutical Benefits Scheme (PBS), which subsidizes the drug for eligible patients. The Australian PI (Product Information) carries the same core warnings as the FDA label and adds a specific note about use during breastfeeding, advising that the drug should be avoided because it is excreted in human milk, a point the FDA label addresses with less specificity.

WHO Model List of Essential Medicines

Amlodipine appears on the World Health Organization (WHO) Model List of Essential Medicines (23rd edition, 2023) as a core antihypertensive. Its inclusion signals that the WHO considers it appropriate for health systems globally to maintain in stock as a first-line treatment for hypertension. WHO Essential Medicines List 2023

Key Post-Market Safety Data and Surveillance

ASCOT-BPLA: The Landmark Outcomes Trial

The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) remains the most influential post-market outcomes study for amlodipine. The trial enrolled 19,257 hypertensive patients with at least three additional cardiovascular risk factors and randomized them to either amlodipine 5 to 10 mg (with perindopril added if needed) or atenolol 50 to 100 mg (with bendroflumethiazide added if needed). The trial was stopped early at a median follow-up of 5.5 years because the amlodipine-based regimen showed a statistically significant 23% relative risk reduction in the primary endpoint of non-fatal MI and fatal coronary heart disease (P<0.0001 for total cardiovascular events). The amlodipine arm also produced a 24% reduction in total cardiovascular events and procedures and an 11% reduction in all-cause mortality, though the mortality difference did not reach statistical significance. ASCOT-BPLA, Lancet 2005

The trial's principal investigator, Professor Peter Sever, stated in the published report that "the advantage of the amlodipine-based over the atenolol-based regimen was not explained by differences in blood pressure alone," a finding that generated lasting debate about whether CCBs carry pleiotropic cardiovascular benefits beyond blood pressure reduction.

FDA Sentinel System Monitoring

The FDA's Sentinel System, which draws on claims data from more than 100 million insured Americans, has conducted periodic safety queries on CCBs, including amlodipine. No Sentinel signal has resulted in a label change for amlodipine related to a newly identified serious adverse event. The system continues to monitor for signals including peripheral edema severity, drug-drug interactions with CYP3A4 substrates, and rare reports of gingival hyperplasia. FDA Sentinel System

Peripheral Edema: The Most Common Adverse Effect

Peripheral edema is the most commonly reported adverse effect of amlodipine in both label studies and post-market surveillance. The approved label reports edema rates of 1.8% at 2.5 mg, 3.0% at 5 mg, and 10.8% at 10 mg in women, with somewhat lower rates in men. This dose-dependent edema results from preferential arteriolar dilation without matched venodilation, increasing transcapillary filtration in the lower limbs. It is not cardiogenic and does not indicate worsening heart failure in most patients. Switching to a renin-angiotensin system (RAS) inhibitor combination may reduce edema incidence, a strategy supported by post-hoc ASCOT-BPLA analyses.

Gingival Hyperplasia

A rare but well-documented adverse effect of dihydropyridine CCBs is gingival overgrowth. The mechanism involves CCB-induced inhibition of folic acid uptake in fibroblasts, altering collagen metabolism in gum tissue. The incidence with amlodipine is lower than with nifedipine but remains clinically relevant. A 2019 systematic review in the Journal of Clinical Periodontology estimated prevalence at approximately 1.7% with amlodipine versus 6.3% with nifedipine. Improved oral hygiene and, in severe cases, drug discontinuation are the recommended management steps. J Clin Periodontol, NCBI

Drug Interactions Flagged in Post-Market Data

The label and subsequent pharmacokinetic studies identify three clinically significant interaction categories:

• CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): May increase amlodipine AUC by 40 to 56%. Monitor blood pressure; a dose reduction to 2.5 mg may be needed.
• CYP3A4 inducers (rifampin, St. John's Wort): May reduce amlodipine exposure and blunt antihypertensive effect. Titration upward with blood pressure monitoring is appropriate.
• Simvastatin: A specific FDA safety communication (2011) established that concomitant use of amlodipine with simvastatin increases simvastatin exposure by approximately 77%, raising the risk of myopathy and rhabdomyolysis. The FDA recommends limiting simvastatin dose to 20 mg/day when co-prescribed with amlodipine. FDA Drug Safety Communication, Simvastatin

Regulatory Considerations in Special Populations

Pregnancy and Lactation

Under the current FDA Pregnancy and Lactation Labeling Rule (PLLR), the amlodipine label states that animal reproduction studies showed fetal harm at doses five times the maximum recommended human dose. Human data are insufficient to establish or exclude risk. Clinicians managing hypertension in pregnancy generally prefer labetalol, nifedipine extended-release, or methyldopa as first-line agents, reserving amlodipine for cases where alternatives are not tolerated. ACOG Practice Bulletin 203, Chronic Hypertension in Pregnancy

Geriatric Patients

The label advises starting at 2.5 mg in elderly patients. A pharmacokinetic study cited in the label found that time to peak plasma concentration was similar in young and elderly subjects, but the AUC increased by approximately 40% in patients over age 65, reflecting reduced hepatic clearance. Blood pressure should be monitored more frequently at initiation and after each dose increase in this group.

Renal Impairment

No amlodipine dose adjustment is required for renal impairment, including patients on hemodialysis. The drug is not removed by dialysis because of its high protein binding (approximately 97.5%). This characteristic makes amlodipine a practical choice in chronic kidney disease (CKD) patients with hypertension, a population that tolerates many other antihypertensives poorly.

Regulatory Status of Amlodipine Combination Products

Amlodipine is an active component in several FDA-approved fixed-dose combination (FDC) products. Each FDC carries its own NDA and label, though the amlodipine component's safety profile is considered consistent across products.

Amlodipine/Valsartan (Exforge, NDA 022108): Approved 2007. Combines CCB with angiotensin receptor blocker (ARB) for patients not adequately controlled on monotherapy.

Amlodipine/Benazepril (Lotrel, NDA 020364): Approved 1995. Combines CCB with ACE inhibitor. Post-market data from the ACCOMPLISH trial (N=11,506) showed that the CCB/ACE inhibitor combination reduced the primary composite of cardiovascular death, MI, and stroke by 20% compared with a thiazide/ACE inhibitor combination (P<0.001). ACCOMPLISH, NEJM 2008

Amlodipine/Olmesartan (Azor, NDA 022100): Approved 2007. An ARB/CCB combination with a label that cross-references the amlodipine safety data from NDA 019787.

Amlodipine/Atorvastatin (Caduet, NDA 021302): Approved 2004. This product combines antihypertensive and lipid-lowering therapy in a single tablet. The amlodipine-simvastatin interaction warning does not apply to this combination because atorvastatin does not carry the same simvastatin dose-limitation signal.

Each combination product label incorporates the amlodipine contraindication (hypersensitivity), the hepatic impairment dose recommendation, and the CYP3A4 interaction data from the parent NDA.

Compliance with Current Labeling Standards

The FDA's 2006 Physician Labeling Rule (PLR) required all NDA holders to reformat labels into the standardized Highlights of Prescribing Information structure. Pfizer submitted a PLR-compliant label for Norvasc, and generic manufacturers have been required to maintain labeling parity under the Pliva v. Mensing and Mutual Pharmaceutical v. Bartlett Supreme Court decisions, which established that generic manufacturers must keep their labels identical to the reference listed drug (RLD).

The FDA's current reference label for amlodipine (NDA 019787) was last substantially updated in 2011, though minor formatting revisions have occurred since then. Any clinician or pharmacist seeking the current label should access it directly through Drugs@FDA rather than relying on third-party database reprints, which may lag behind official updates.

The Endocrine Society and American Heart Association both cite amlodipine as an acceptable first-line antihypertensive in clinical practice guidelines. The AHA/ACC 2017 Hypertension Guideline states: "Thiazide diuretics, CCBs, and ACE inhibitors or ARBs are recommended as first-line therapy for most adults with hypertension," a category that includes amlodipine as the most widely prescribed CCB in the United States. AHA/ACC 2017 Hypertension Guideline

Clinicians prescribing amlodipine for a patient also taking simvastatin should cap the simvastatin dose at 20 mg/day per the 2011 FDA safety communication.